ED90 of Liposomal Bupivacaine and Hydrochloric Bupivacaine for Stellate Ganglion Block

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2600116174

Enrollment

Unknown

Registered

2026-01-06

Start date

2026-01-16

Completion date

Unknown

Last updated

2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nerve block

Interventions

Liposomal Bupivacaine Group:Stellate ganglion block using liposomal bupivacaine

Bupivacaine Hydrochloride Group:Stellate ganglion block using Bupivacaine Hydrochloride

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Age: 18-75 years, regardless of gender;

Exclusion criteria

Exclusion criteria: 1. History of allergy to amide-type local anesthetics; 2. Infection or anatomic anomalies at the puncture site; 3. Pregnant or lactating women; 4. Severe cardiovascular or respiratory diseases; 5. Long-term use of opioids (>30 mg/d morphine equivalents).

Design outcomes

Primary

Measure	Time frame
ED90 of the drug;	—

Secondary

Measure	Time frame
Horner syndrome;Relevant Blood Factors;	—

Countries

China

Contacts

Public ContactQinghang Xuan

The First Affiliated Hospital of Dali University, Dali, Yunnan

xuanqinghang@163.com+86 152 5306 6603

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026